NCT04382846 is a Phase 3 clinical trial of Nitazoxanide in COVID, sponsored by Tanta University.

Who is sponsoring NCT04382846?

NCT04382846 is sponsored by Tanta University.

What drugs are being tested in NCT04382846?

Interventions in NCT04382846: Nitazoxanide.

What condition does NCT04382846 study?

NCT04382846 studies COVID, Corona Virus Infection.

Is NCT04382846 still recruiting?

NCT04382846 is currently recruiting now. Last updated 4 December 2020.

Last reviewed 2020-12-04 · How we verify

NCT04382846

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Regimens in COVID-19 Treatment

Recruiting now Phase 3 Last updated 4 December 2020

What this trial tests

Phase 3 trial testing Nitazoxanide in COVID in 160 participants. Currently enrolling.

Timeline

8 May 2020

Primary endpoint
1 December 2030

1 December 2030

Quick facts

Lead sponsor	Tanta University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	8 May 2020
Primary completion	1 December 2030
Estimated completion	1 December 2030
Sites	2 locations across Egypt

Drugs / interventions tested

Nitazoxanide (NITAZOXANIDE) — full drug profile →

Conditions studied

COVID — all drugs for COVID →
Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

Tanta University

Who can join

18 and older, any sex, with COVID or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Wuhan to World: The COVID-19 Pandemic.
Kumar A, Singh R, Kaur J, Pandey S, et al · · 2021 · cited 109× · PMID 33859951 · DOI 10.3389/fcimb.2021.596201
Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, Gould S, et al · · 2021 · cited 102× · PMID 34318930 · DOI 10.1002/14651858.cd015017.pub2
A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.
Lokhande AS, Devarajan PV. · · 2021 · cited 69× · PMID 33227285 · DOI 10.1016/j.ejphar.2020.173748
Antibiotics for the treatment of COVID-19.
Popp M, Stegemann M, Riemer M, Metzendorf MI, et al · · 2021 · cited 60× · PMID 34679203 · DOI 10.1002/14651858.cd015025
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
Homolak J, Kodvanj I. · · 2020 · cited 54× · PMID 32522674 · DOI 10.1016/j.ijantimicag.2020.106044
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
Kaur H, Shekhar N, Sharma S, Sarma P, et al · · 2021 · cited 52× · PMID 33389725 · DOI 10.1007/s43440-020-00195-y
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA, Wagstaff KM. · · 2020 · cited 52× · PMID 32942671 · DOI 10.3390/cells9092100

Verify or expand the search:

Other trials of Nitazoxanide

Trials testing the same drug.

NCT06993974 — Nitazoxanide in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07086937 — Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children · NA · completed
NCT06010992 — Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus · Phase 2 · unknown
NCT05368935 — Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects · Phase 1 · completed
NCT05116826 — Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients · Phase 1 · completed

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04362150 — Long-term Impact of Infection With Novel Coronavirus (COVID-19) · recruiting

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04382846 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 4 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04382846.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing